NCT00414076View on ClinicalTrials.gov

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 19, 2006

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions
LeiomyosarcomaUterine Neoplasm
Interventions
DRUG

Letrozole

2.5 mg Tablet By Mouth Daily for 12 Weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00414076 - Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | Biotech Hunter | Biotech Hunter